Navigation Links
European Urology: Editorial about REDUCE trial underlines value of dutasteride
Date:5/25/2010

Arnhem -- On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial by Fritz H. Schrder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology (EAU).

The long-expected final report of the REDUCE trial appeared on April 1, 2010 in the New England Journal of Medicine [1] together with a commentary entitled 'Chemoprevention of prostate cancer' by Dr Patrick Walsh. What were the noteworthy items of the editorial?

  • The REDUCE trial, contrary to the Prostate Cancer Prevention Trial (PCPT) [2], is performed in men who would have been candidates for biopsy anyway because of PSA values of 2.5 10 ng/ml, making the reduction of the chance of a positive biopsy of 23% clinically relevant.

  • The mechanism of dutasteride is not primarily prevention but the inhibition of growth of small, well differentiated cancers as a result of the intracellular reduction of 5a-dihydrotestosterone (DHT). This mechanism which results in the prevention of disease progression is called 'tertiary prevention' and in this setting can be seen as treatment of minimal disease. This effect is seen in spite of the simultaneous, up to 40 times increase in testosterone (T) [3]. It remains unclear why the rise in T does not prevent the effect of the reduction in DHT.

  • The report indicates a small difference in cardiovascular side effects in disadvantage of dutasteride. The long-term general health effects obviously remain unknown at this time.

  • Unanswered issues: is dutasteride useful in reducing unnecessary biopsies and does it help to selectively identify aggressive disease? The reported data show that in men with an indication of periodic biopsies the reduction in the detection of potentially over-diagnosed cancers is 28.2% (table 3 in [1]).

  • More detailed analyses are warranted. Extended follow-up to monitor, for example, the outcome of relevant endpoints such as delayed diagnosis of aggressive cancers, progression to metastatic disease and disease-specific mortality in comparison to the control population will be of great scientific value in spite of the unblinding of the trial and should therefore have top priority.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. European Cancer Organization supports a revision of the EU Clinical Trials Directive
2. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
3. Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
4. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
5. The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center
6. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
7. Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems
8. Lower detection of prostate cancer with PSA screening in US than in a European randomized trial
9. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
10. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
11. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced ... Emergency Medicine , an emergency medicine professional association, to support the organization's newly ... The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market ... Technologies, Participants, and Environment" research report indicates that ... over $149 billion by 2020 growing at a ... of companion diagnostics and targeted therapeutics and is ...
(Date:2/9/2016)... REDWOOD CITY, Calif. , Feb. 9, 2016 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it will release financial results for the fourth quarter ... Monday, February 29, 2016. Company management will host a ... p.m. Eastern Time) on Monday, February 29, 2016. ...
(Date:2/9/2016)... , Feb. 9, 2016  Insulet Corporation (NASDAQ: PODD ... insulin pump technology with its OmniPod ® ... Lemoine has been appointed to Insulet,s Board of Directors. ... directors, eight of whom are independent. --> ... of audit and finance experience and a deep knowledge of ...
Breaking Medicine Technology: